What Lies Next for the Precision Medicine Community
Following the close of ASCO, critical conversations have sparked around the future direction of precision medicine and how emerging biomarker data will change the trajectory of the field.
Top biomarker and IVD headlines included:
- Myriad Genetics launching the first prostate cancer biomarker test to combine both genomics and digital pathology artificial intelligence with Prolaris® + AI
- Illumina announcing the launch of a new MRD product, as the first whole-genome kit facilitating
- Guardant Health demonstrating the validity of Guardant360 Liquid CDx showcasing new performance data as a comprehensive pan-cancer companion diagnostic
- Natera unveiling its new digital Annotation platform, integrating clinical, treatment and genomic data to deliver longitudinal, multimodal patient journeys through a single interface
Now is the time to take these conversations further.
The upcoming 16th World Clinical Biomarkers & Companion Diagnostics Summit is the prime place to do just that. Convening the complete precision medicine development value chain, across a diverse range of IVD technologies and disease areas, it remains the next major, must-attend precision medicine event for leaders looking to stay ahead in this ever-evolving landscape.
Delve into the Brand-New Agenda
- Free* Attendance for Representatives from Biopharma & Academia
- Your Globally Leading Biomarker & Companion Diagnostics Forum
- Access Numerous Strategic Rx-Dx Co-Development & Partnership Selection Panels
- Partake in Multiple Biomarker Sessions Spanning Oncology, Hematology & Neurological, Chronic, Autoimmune & Rare Diseases
- Discover Brand-New Case Studies on Digital Pathology, Multimodal Data & AI-Enabled Precision Medicine
- Take Advantage of Unmatched, Exclusive Networking & Partnerships Opportunities
